Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R8GR
|
|||
| Former ID |
DCL000907
|
|||
| Drug Name |
OPC-14523
|
|||
| Synonyms |
OPC-14523; UNII-1981OTB4DS; 1981OTB4DS; CHEMBL294144; 145969-30-8; OPC-14523 free base; SCHEMBL5022801; ZINC598353; BDBM50005656; 1-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-5-methoxy-3,4-dihydro-2-quinolinone; L001554; 2(1H)-Quinolinone, 1-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-3,4-dihydro-5-methoxy-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bulimia nervosa [ICD-11: 6B81; ICD-10: F50.2, F50.3] | Phase 2 | [1] | |
| Mood disorder [ICD-11: 6A60-6E23] | Phase 2 | [1] | ||
| Female sexual arousal dysfunction [ICD-11: HA01.1; ICD-9: 302.7] | Phase 1 | [1] | ||
| Company |
Otsuka Pharmaceutical and Vela Pharmaceuticals; Pharmos and Otsaku
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H28ClN3O2
|
|||
| Canonical SMILES |
COC1=CC=CC2=C1CCC(=O)N2CCCN3CCN(CC3)C4=CC(=CC=C4)Cl
|
|||
| InChI |
1S/C23H28ClN3O2/c1-29-22-8-3-7-21-20(22)9-10-23(28)27(21)12-4-11-25-13-15-26(16-14-25)19-6-2-5-18(24)17-19/h2-3,5-8,17H,4,9-16H2,1H3
|
|||
| InChIKey |
TZZGTNZBLPCBIS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 145969-30-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Modulator | [2] |
| Opioid receptor sigma 1 (OPRS1) | Target Info | Modulator | [2] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
| miR-targeted genes in lymphocytes - TarBase | ||||
| Serotonin HTR1 Group and FOS Pathway | ||||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66. | |||
| REF 2 | Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.